Video

Dr. Wistuba on Biomarkers for Immunotherapy in Lung Cancer

Ignacio I. Wistuba, MD, chair, Department of Translational Molecular Pathology, Division of Pathology/Medicine, The University of Texas MD Anderson Cancer Center, discusses biomarkers for immunotherapy in lung cancer.

Ignacio I. Wistuba, MD, chair, Department of Translational Molecular Pathology, Division of Hematology/Pathology, The University of Texas MD Anderson Cancer Center, discusses the current landscape of biomarkers for immunotherapy in lung cancer.

PD-L1 expression and tumor mutation burden (TMB) are the two prominent biomarkers, but there’s still much room for improvement to advance these even further, says Wistuba. The most important aspect of modifying these imperfections is a set of universal guidelines for utilizing these biomarkers. Evaluating PD-L1 as a biomarker has become effective, but only after a few years of research and discussion. The same thing is happening now with TMB, Wistuba says.

There are still ongoing clinical trials to determine a clear genotyping platform in TMB that will result in the proper treatment. For the future, Wistuba adds, a deeper understanding of tumor profiling is necessary to develop new biomarkers.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity